High rates of 30-day mortality in patients with cirrhosis and COVID-19
Massimo Iavarone(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alessandro Soria(University of Milano-Bicocca), Elisabetta Buscarini(Azienda Ospedaliera Ospedale Maggiore), Giovanni Perricone(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Angiola Spinetti(University of Brescia), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marianna Pedaci(University of Milan), Martina De Luca(University of Salerno), Alessandro Rimondi(University of Milan), Alessio Aghemo, Mauro Viganò(Ospedale San Giuseppe), Pietro Invernizzi(Azienda Ospedaliera San Gerardo), M. Triolo(Ospedale Papa Giovanni XXIII), Paolo Bonfanti(University of California San Diego), Nicola Pugliese(Humanitas University), S. Fagiuoli(Ospedale Papa Giovanni XXIII), Maria Grazia Rumi(University of Milan), L Belli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), P. Del Poggio, Canio Carriero(University of Brescia), Sara Massironi(Azienda Ospedaliera San Gerardo)
Cited by 392
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
|Hepatology|2012|404
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
|Nature Genetics|2013|398
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
|Journal of Hepatology|2020|361